Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that management will present at the H.C. Wainwright Global Life Sciences Conference taking place on March 9-10, 2021. The presentation will be available on-demand through the H.C. Wainwright conference portal available here, starting at 7 a.m. ET on Tuesday...
NEW YORK, NY / ACCESSWIRE / March 2, 2021 / Vaxart, Inc. (NASDAQ:VXRT) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 2, 2021 at 4:30 PM Eastern Time.
VAXART, INC. (VXRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Vaxart (NASDAQ: VXRT) made some investors quite wealthy in 2020. Its shares skyrocketed more than 1,500% on increasing enthusiasm about its tablet COVID-19 vaccine program. Vaxart's big sell-off in February underscores the main hurdle the company must jump to deliver huge returns for investors.
VXA-CoV2-1 oral COVID-19 vaccine candidate targeting both the S and N proteins is planned to advance to Phase 2 testing during Q2 2021Cash and cash equivalents of $126.9 million as of December 31, 2020Conference call and webcast focused on our COVID-19 strategy scheduled for Tuesday, March 2, 2021 at 4:30pm ET SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) a clinical-stage biotechnology company developing oral recombinant vaccines that are administered...
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will host a conference call and provide a business update at 4:30 PM ET on Tuesday, March 2, 2021. Conference Call Dial-In & Webcast Information:Date: Tuesday, March 2, 2021Time:4:30 PM Eastern TimeDomestic:877-407-0784International:201-689-8560Conference ID:137169...
Imagine a vaccine without the jab: That's Vaxart's specialty. The clinical-stage biotech company is developing oral vaccines for a variety of viruses -- including SARS-CoV-2, the virus that causes COVID-19. The company's shares soared more than 1,500% last year as Vaxart's investigational coronavirus vaccine made it through preclinical studies and began a human trial.
These are the small cap stocks with the best value, fastest growth, and most momentum for February 2021.